| Jacqueline Ann Ots, PENDING | |
|
855 N Westhaven Dr, Oshkosh, WI 54904-7668 | |
| (920) 303-8700 | |
| Not Available |
| Full Name | Jacqueline Ann Ots |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 4 Years |
| Location | 855 N Westhaven Dr, Oshkosh, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003456823 | NPI | - | NPPES |
| 100099992 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 10085 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Aurora Medical Ctr Oshkosh | Oshkosh, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aurora Medical Group, Inc. | 6709794258 | 3207 |
News Archive
The most common genetic subtype of lung cancer, which has long defied treatment with targeted therapies, has had its growth halted by a combination of two already-in-use drugs in laboratory and animal studies, setting the stage for clinical trials of the drugs in patients, researchers at Dana-Farber Cancer Institute and other scientists report in a new study.
In this interview, News-Medical talks to Laura Nea, Vice President of Quality and Regulatory Management at Tecan, about the upcoming changes to the regulations surrounding in-vitro diagnostics
Another clue to the workings of trachoma - the world's leading infectious cause of blindness - has been revealed in a new study published in BMC Infectious Diseases. Researchers identified markers of genetic regulation present in the early stages of infection that could predispose children to developing the condition in its long-term, severe form.
New research led by Hana El-Samad of the University of California, San Francisco, and the Chan-Zuckerberg Biohub confirmed the beneficial use of an antiviral therapeutic called SARSNotch, which uses a combination of the SynNotch platform and de-novo designed protein binders. SARSNotch uses sentinel T cells to detect and mount a genetic response toward the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.
› Verified 3 days ago
| Entity Name | Baycare Clinic Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588609648 PECOS PAC ID: 4385554328 Enrollment ID: O20031105000087 |
News Archive
The most common genetic subtype of lung cancer, which has long defied treatment with targeted therapies, has had its growth halted by a combination of two already-in-use drugs in laboratory and animal studies, setting the stage for clinical trials of the drugs in patients, researchers at Dana-Farber Cancer Institute and other scientists report in a new study.
In this interview, News-Medical talks to Laura Nea, Vice President of Quality and Regulatory Management at Tecan, about the upcoming changes to the regulations surrounding in-vitro diagnostics
Another clue to the workings of trachoma - the world's leading infectious cause of blindness - has been revealed in a new study published in BMC Infectious Diseases. Researchers identified markers of genetic regulation present in the early stages of infection that could predispose children to developing the condition in its long-term, severe form.
New research led by Hana El-Samad of the University of California, San Francisco, and the Chan-Zuckerberg Biohub confirmed the beneficial use of an antiviral therapeutic called SARSNotch, which uses a combination of the SynNotch platform and de-novo designed protein binders. SARSNotch uses sentinel T cells to detect and mount a genetic response toward the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.
› Verified 3 days ago
| Entity Name | Aurora Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427271378 PECOS PAC ID: 6709794258 Enrollment ID: O20031105000725 |
News Archive
The most common genetic subtype of lung cancer, which has long defied treatment with targeted therapies, has had its growth halted by a combination of two already-in-use drugs in laboratory and animal studies, setting the stage for clinical trials of the drugs in patients, researchers at Dana-Farber Cancer Institute and other scientists report in a new study.
In this interview, News-Medical talks to Laura Nea, Vice President of Quality and Regulatory Management at Tecan, about the upcoming changes to the regulations surrounding in-vitro diagnostics
Another clue to the workings of trachoma - the world's leading infectious cause of blindness - has been revealed in a new study published in BMC Infectious Diseases. Researchers identified markers of genetic regulation present in the early stages of infection that could predispose children to developing the condition in its long-term, severe form.
New research led by Hana El-Samad of the University of California, San Francisco, and the Chan-Zuckerberg Biohub confirmed the beneficial use of an antiviral therapeutic called SARSNotch, which uses a combination of the SynNotch platform and de-novo designed protein binders. SARSNotch uses sentinel T cells to detect and mount a genetic response toward the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.
› Verified 3 days ago
| Entity Name | Lakeshore Medical Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003861188 PECOS PAC ID: 7719890730 Enrollment ID: O20031106000481 |
News Archive
The most common genetic subtype of lung cancer, which has long defied treatment with targeted therapies, has had its growth halted by a combination of two already-in-use drugs in laboratory and animal studies, setting the stage for clinical trials of the drugs in patients, researchers at Dana-Farber Cancer Institute and other scientists report in a new study.
In this interview, News-Medical talks to Laura Nea, Vice President of Quality and Regulatory Management at Tecan, about the upcoming changes to the regulations surrounding in-vitro diagnostics
Another clue to the workings of trachoma - the world's leading infectious cause of blindness - has been revealed in a new study published in BMC Infectious Diseases. Researchers identified markers of genetic regulation present in the early stages of infection that could predispose children to developing the condition in its long-term, severe form.
New research led by Hana El-Samad of the University of California, San Francisco, and the Chan-Zuckerberg Biohub confirmed the beneficial use of an antiviral therapeutic called SARSNotch, which uses a combination of the SynNotch platform and de-novo designed protein binders. SARSNotch uses sentinel T cells to detect and mount a genetic response toward the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.
› Verified 3 days ago
| Entity Name | Aurora Advanced Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265629133 PECOS PAC ID: 3375625833 Enrollment ID: O20080123000694 |
News Archive
The most common genetic subtype of lung cancer, which has long defied treatment with targeted therapies, has had its growth halted by a combination of two already-in-use drugs in laboratory and animal studies, setting the stage for clinical trials of the drugs in patients, researchers at Dana-Farber Cancer Institute and other scientists report in a new study.
In this interview, News-Medical talks to Laura Nea, Vice President of Quality and Regulatory Management at Tecan, about the upcoming changes to the regulations surrounding in-vitro diagnostics
Another clue to the workings of trachoma - the world's leading infectious cause of blindness - has been revealed in a new study published in BMC Infectious Diseases. Researchers identified markers of genetic regulation present in the early stages of infection that could predispose children to developing the condition in its long-term, severe form.
New research led by Hana El-Samad of the University of California, San Francisco, and the Chan-Zuckerberg Biohub confirmed the beneficial use of an antiviral therapeutic called SARSNotch, which uses a combination of the SynNotch platform and de-novo designed protein binders. SARSNotch uses sentinel T cells to detect and mount a genetic response toward the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jacqueline Ann Ots, PENDING Po Box 735044, Chicago, IL 60673-5044 Ph: (920) 303-8700 | Jacqueline Ann Ots, PENDING 855 N Westhaven Dr, Oshkosh, WI 54904-7668 Ph: (920) 303-8700 |
News Archive
The most common genetic subtype of lung cancer, which has long defied treatment with targeted therapies, has had its growth halted by a combination of two already-in-use drugs in laboratory and animal studies, setting the stage for clinical trials of the drugs in patients, researchers at Dana-Farber Cancer Institute and other scientists report in a new study.
In this interview, News-Medical talks to Laura Nea, Vice President of Quality and Regulatory Management at Tecan, about the upcoming changes to the regulations surrounding in-vitro diagnostics
Another clue to the workings of trachoma - the world's leading infectious cause of blindness - has been revealed in a new study published in BMC Infectious Diseases. Researchers identified markers of genetic regulation present in the early stages of infection that could predispose children to developing the condition in its long-term, severe form.
New research led by Hana El-Samad of the University of California, San Francisco, and the Chan-Zuckerberg Biohub confirmed the beneficial use of an antiviral therapeutic called SARSNotch, which uses a combination of the SynNotch platform and de-novo designed protein binders. SARSNotch uses sentinel T cells to detect and mount a genetic response toward the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.
› Verified 3 days ago
Ms. Joyce E Abbott, APNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 414 Doctors Ct, Oshkosh, WI 54901 Phone: 920-303-5100 Fax: 920-303-5150 | |
Xing Kong, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 855 N Westhaven Dr, Oshkosh, WI 54904 Phone: 920-303-8700 Fax: 920-303-8827 | |
Mrs. Jennifer Mladucky, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2700 W 9th Ave, Suite 11, Oshkosh, WI 54904 Phone: 920-236-1555 | |
Nichole R Nelson, APNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 600 N Westhaven Dr, Oshkosh, WI 54904 Phone: 920-237-5000 | |
Lindsay R Locklar, CNM Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 855 N Westhaven Dr, Oshkosh, WI 54904 Phone: 920-456-7300 | |
Hannah Challoner, APNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1300 South Drive, Oshkosh, WI 54901 Phone: 920-235-4910 |